Marc Diamond on Might SORL1 Bind Tau in Glia, Fuel Its Aggregation?

COMMENT The take-home message for me is that any assertion of a single protein “receptor” for tau at the surface should be taken with a grain of salt. This paper purports to show that SORL1 is a “receptor” for tau. However, one of the final figures indicates that

Gregory Petsko on Might SORL1 Bind Tau in Glia, Fuel Its Aggregation?

COMMENT The paper is interesting and potentially important. That retromer-regulated trafficking is important in tauopathies, including Alzheimer’s disease, is well-established (e.g., Mishra et al., 2023). However, the direct binding of tau to SORL1 is a new findi

Kenneth Kosik on Might SORL1 Bind Tau in Glia, Fuel Its Aggregation?

COMMENT This paper by J.M. Cooper et al. is a well-executed study that advances our thinking about the route tau travels once internalized. In essence, the problem we face is that, internalized via LRP1 through which it enters endosomes, tau must escape the endos

George King

Atlanta, United States

PAPER Jacobsen L, Madsen P, Jacobsen C, Nielsen MS, Gliemann J, Petersen CM

Activation and functional characterization of the mosaic receptor SorLA/LR11.

J Biol Chem. 2001 Jun 22;276(25):22788-96. Epub 2001 Apr 9 PubMed: 11294867

Sooyeon Jeon

Department of Intelligent Precision Healthcare Convergence
Suwon, Korea, Republic of

Peter Benson

Notice of Special Interest (NOSI): Promoting Data Reuse for Health Research (NOT-OD-24-096)

GRANT Friday, May 3, 2024- 3:45pm National Institutes of Health This Notice of Special Interest (NOSI) solicits competitive revision applications. Multiple due dates; see announcement. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-24-096.html 04 Nov 2

Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional) (PAR-24-202)

GRANT Friday, May 3, 2024- 3:45pm National Institutes of Health August 30, 2024. https://grants.nih.gov/grants/guide/pa-files/PAR-24-202.html 31 Aug 2024

Notice of Information: Technical Assistance Webinars for PAR-24-206: Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional) (NOT-TR-24-024)

GRANT Friday, May 3, 2024- 3:30pm National Center for Advancing Translational Sciences Two identical technical assistance webinars will be conducted. 1) May 22, 2024 – 9:00 am to 10:30 am Eastern Time. 2) June 3, 2024 – 3:00 pm to 4:30 pm Eastern Time. https://

PAPER Goldberg A, Xie B, Shi L

The Molecular Mechanism of Positive Allosteric Modulation at the Dopamine D1 Receptor.

Int J Mol Sci. 2023 Aug 16;24(16) PubMed: 37629030

PAPER Chen J, Song Y, Ma L, Jin Y, Yu J, Guo Y, Huang Y, Pu X

Computational insights into diverse binding modes of the allosteric modulator and their regulation on dopamine D1 receptor.

Comput Biol Med. 2024 May;173:108283. Epub 2024 Mar 20 PubMed: 38552278

PAPER Sibley DR, Luderman KD, Free RB, Shi L

Novel Cryo-EM structures of the D1 dopamine receptor unlock its therapeutic potential.

Signal Transduct Target Ther. 2021 May 22;6(1):205. PubMed: 34023856

PAPER Bai M, Jia S, Zhang J, Cheng HG, Cong H, Liu S, Huang Z, Huang Y, Chen X, Zhou Q

A Modular Approach for Diversity-Oriented Synthesis of 1,3-trans-Disubstituted Tetrahydroisoquinolines: Seven-Step Asymmetric Synthesis of Michellamines B and C.

Angew Chem Int Ed Engl. 2022 Aug 1;61(31):e202205245. Epub 2022 Jun 17 PubMed: 35616270

PAPER Teng X, Chen S, Nie Y, Xiao P, Yu X, Shao Z, Zheng S

Ligand recognition and biased agonism of the D1 dopamine receptor.

Nat Commun. 2022 Jun 8;13(1):3186. PubMed: 35676276